PMID- 20004333
OWN - NLM
STAT- MEDLINE
DCOM- 20100304
LR  - 20211203
IS  - 0399-8320 (Print)
IS  - 0399-8320 (Linking)
VI  - 33 Suppl 4
DP  - 2009 Nov
TI  - [Antitumoral effect of proliferation signal inhibitors].
PG  - S263-7
LID - 10.1016/S0399-8320(09)73164-1 [doi]
AB  - The mammalian target of rapamycin (mTOR) is implicated in cell growth especially 
      during cancer development and progression. Its action is dependent on well known 
      oncogenic pathways that regulate tumor cell growth and cell cycle progression, in 
      response to different stimuli. Sirolimus, temsirolimus and everolimus are 
      specific inhibitors of mTOR that have originally been characterized by their 
      antifungal and immunosuppressive properties, but also significantly inhibit 
      cancer cells'proliferation, invasion, and metastasis, and promote apoptosis. In 
      addition, mTOR inhibitors display potent antiangiogenic properties by the 
      suppression of vascular endothelial growth factor signal transduction. The 
      antitumoral effects of mTOR inhibitors, as a monotherapy or in combination with 
      tyrosine kinase inhibitors or usual cytotoxic agents, have been extensively 
      suggested in preclinical studies, including animal models. In a clinical setting, 
      preliminary reports have demonstrated that mTOR inhibitors use is associated with 
      an acceptable safety profile. Currently, mTOR inhibitors are tested in multiple 
      trials and various cancer types, usually in intermittent schedules to avoid 
      significant immunosuppression. Of particular interest is the use of mTOR 
      inhibitors in the field of organ transplantation, including liver 
      transplantation, in preventive or curative strategies, for the treatment of 
      recurrent hepatocellular carcinoma and de novo post-transplantation malignancies.
FAU - Dumortier, J
AU  - Dumortier J
AD  - Unite de transplantation hepatique, Hopital Edouard Herriot, pavillon H bis, 
      Lyon, France. jerome.dumortier@chu-lyon.fr
LA  - fre
PT  - Journal Article
TT  - Effet antitumoral des inhibiteurs du signal de proliferation.
PL  - France
TA  - Gastroenterol Clin Biol
JT  - Gastroenterologie clinique et biologique
JID - 7704825
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 624KN6GM2T (temsirolimus)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Angiogenesis Inhibitors
MH  - Animals
MH  - *Antineoplastic Agents
MH  - Apoptosis/drug effects
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents
MH  - Intracellular Signaling Peptides and Proteins/*antagonists & inhibitors
MH  - Liver Transplantation
MH  - Neoplasm Invasiveness/prevention & control
MH  - Neoplasm Metastasis/prevention & control
MH  - Protein Serine-Threonine Kinases/*antagonists & inhibitors
MH  - Sirolimus/analogs & derivatives/therapeutic use
MH  - TOR Serine-Threonine Kinases
EDAT- 2009/12/17 06:00
MHDA- 2010/03/05 06:00
CRDT- 2009/12/17 06:00
PHST- 2009/12/17 06:00 [entrez]
PHST- 2009/12/17 06:00 [pubmed]
PHST- 2010/03/05 06:00 [medline]
AID - S0399-8320(09)73164-1 [pii]
AID - 10.1016/S0399-8320(09)73164-1 [doi]
PST - ppublish
SO  - Gastroenterol Clin Biol. 2009 Nov;33 Suppl 4:S263-7. doi: 
      10.1016/S0399-8320(09)73164-1.